AVIR Q4 2022 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$15M

Operating Income

-$40M

Net Income

-$34M

EPS (Diluted)

$-0.41

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$667M

Total Liabilities

$26M

Stockholders' Equity

$641M

Cash & Equivalents

$647M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$192M	-100.0%
Gross Profit	-$15M	$134M	-111.0%
Operating Income	-$40M	$121M	-132.9%
Net Income	-$34M	$117M	-129.4%